The Cambridge biotech reported that it has the ‘potential’ to prevent infection from the virus.
A closely
watched experimental vaccine for COVID-19 developed by Cambridge biotech
Moderna produced antibodies in eight healthy volunteers similar to
those found in people who
recovered from the disease, suggesting that
the vaccine “has the potential to prevent” infection,
according to a
company executive.
The
encouraging results from the first phase of a clinical trial buoyed
investors, boosting
Moderna’s stock by nearly 20 percent and helping to
spark a major rally on Wall Street, with
the Dow Jones industrial
average closing up just shy of 4 percent.
More
than 100 experimental vaccines are in the works as drug firms, academic
laboratories,
and governments around the globe scramble to develop a
way to prevent COVID-19, which has
killed more than 90,000 people in the
United States and 315,000 worldwide. The potential
financial reward for
the first company that markets a successful vaccine could be worth
billions of dollars.
تعليقات: 0
إرسال تعليق